Novartis Tells China Media Diovan Safe In Wake Of Japan Data Issues
This article was originally published in PharmAsia News
Executive Summary
A Novartis International AG official in China said Diovan (valsartan) has a 15-year market history and extensive use globally, emphasizing its safety in response to a controversy over adverse drug reactions and falsified efficacy data in Japan for the drug.